CTLA4 and melanoma: It is not clear how microbial B vitamin biosynthesis may diminish immunotherapy response; yet interestingly, metagenomic pantothenate and riboflavin biosynthesis were both associated with resistance to colitis in melanoma patients on anti-CTLA-4 immunotherapy [43], perhaps indicative of their effects on immunity.